{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T01:25:27Z","timestamp":1794273927540,"version":"4.9.0"},"reference-count":45,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,5,30]],"date-time":"2023-05-30T00:00:00Z","timestamp":1685404800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["annalsofoncology.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1016\/j.annonc.2023.05.009","type":"journal-article","created":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T09:10:12Z","timestamp":1685610612000},"page":"693-702","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":58,"title":["IMscin001 Part 2: a randomised phase III, open-label, multicentre study examining the pharmacokinetics, efficacy, immunogenicity, and safety of atezolizumab subcutaneous versus intravenous administration in previously treated locally advanced or metastatic non-small-cell lung cancer and pharmacokinetics comparison with other approved indications"],"prefix":"10.1016","volume":"34","author":[{"given":"M.","family":"Burotto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Z.","family":"Zvirbule","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Mochalova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Runglodvatana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Herraez-Baranda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.N.","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Shearer-Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"X.","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Tosti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.A.","family":"Zanghi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Leutgeb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Felip","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"22","key":"10.1016\/j.annonc.2023.05.009_bib1","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1056\/NEJMoa1809615","article-title":"Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer","volume":"379","author":"Schmid","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"23","key":"10.1016\/j.annonc.2023.05.009_bib2","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1056\/NEJMoa1809064","article-title":"First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer","volume":"379","author":"Horn","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"10064","key":"10.1016\/j.annonc.2023.05.009_bib3","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S0140-6736(16)32455-2","article-title":"Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial","volume":"389","author":"Balar","year":"2017","journal-title":"Lancet"},{"issue":"20","key":"10.1016\/j.annonc.2023.05.009_bib4","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"10240","key":"10.1016\/j.annonc.2023.05.009_bib5","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1016\/S0140-6736(20)30934-X","article-title":"Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAFV600 mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial","volume":"395","author":"Gutzmer","year":"2020","journal-title":"Lancet"},{"issue":"10308","key":"10.1016\/j.annonc.2023.05.009_bib6","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1016\/S0140-6736(21)02098-5","article-title":"Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial","volume":"398","author":"Felip","year":"2021","journal-title":"Lancet"},{"issue":"14","key":"10.1016\/j.annonc.2023.05.009_bib7","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1056\/NEJMoa1917346","article-title":"Atezolizumab for first-line treatment of PD-L1-selected patients with NSCLC","volume":"383","author":"Herbst","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"10122","key":"10.1016\/j.annonc.2023.05.009_bib8","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/S0140-6736(17)33297-X","article-title":"Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial","volume":"391","author":"Powles","year":"2018","journal-title":"Lancet"},{"issue":"suppl 15","key":"10.1016\/j.annonc.2023.05.009_bib9","article-title":"Phase II study of atezolizumab in advanced alveolar soft part sarcoma (ASPS)","volume":"39","author":"Naqash","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"issue":"10066","key":"10.1016\/j.annonc.2023.05.009_bib10","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0140-6736(16)32517-X","article-title":"Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial","volume":"389","author":"Rittmeyer","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.annonc.2023.05.009_bib11","unstructured":"European Medicines Agency. Tecentriq. Summary of Product Characteristics. 2023. Available at https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/tecentriq-epar-product-information_en.pdf (Accessed 20 June 2023)."},{"key":"10.1016\/j.annonc.2023.05.009_bib12","unstructured":"Health Canada. Tecentriq Product Monograph. 2023. Available at\u00a0https:\/\/www.rochecanada.com\/PMs\/Tecentriq\/Tecentriq_PM_E.pdf (Accessed 20 June 2023)."},{"key":"10.1016\/j.annonc.2023.05.009_bib13","unstructured":"US Food and Drug Administration. Tecentriq. Highlights of Prescribing Information. 2022. Available at https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/761034s043lbl.pdf (Accessed 28 November 2022)."},{"issue":"5","key":"10.1016\/j.annonc.2023.05.009_bib14","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1007\/s40259-018-0295-0","article-title":"Subcutaneous administration of biotherapeutics: an overview of current challenges and opportunities","volume":"32","author":"Bittner","year":"2018","journal-title":"BioDrugs"},{"issue":"4","key":"10.1016\/j.annonc.2023.05.009_bib15","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1093\/annonc\/mdw685","article-title":"Preference for subcutaneous or intravenous administration of rituximab among patients with untreated CD20+ diffuse large B-cell lymphoma or follicular lymphoma: results from a prospective, randomized, open-label, crossover study (PrefMab)","volume":"28","author":"Rummel","year":"2017","journal-title":"Ann Oncol"},{"issue":"10","key":"10.1016\/j.annonc.2023.05.009_bib16","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1016\/S1470-2045(13)70383-8","article-title":"Preference for subcutaneous or intravenous administration of trastuzumab in patients with HER2-positive early breast cancer (PrefHer): an open-label randomised study","volume":"14","author":"Pivot","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.annonc.2023.05.009_bib17","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.ejca.2021.03.047","article-title":"Preference for the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive early breast cancer (PHranceSCa): a randomised, open-label phase II study","volume":"152","author":"O\u2019Shaughnessy","year":"2021","journal-title":"Eur J Cancer"},{"issue":"28","key":"10.1016\/j.annonc.2023.05.009_bib18","doi-asserted-by":"crossref","first-page":"3267","DOI":"10.2217\/fon-2019-0368","article-title":"Humanistic and economic impact of subcutaneous versus intravenous administration of oncology biologics","volume":"15","author":"Anderson","year":"2019","journal-title":"Future Oncol"},{"key":"10.1016\/j.annonc.2023.05.009_bib19","first-page":"1","article-title":"A\u00a0systematic review of time and resource use costs of subcutaneous versus intravenous administration of oncology biologics in a hospital setting","volume":"23","author":"McCloskey","year":"2022","journal-title":"Pharmacoecon Open"},{"issue":"1","key":"10.1016\/j.annonc.2023.05.009_bib20","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1080\/10717544.2018.1551442","article-title":"ENHANZE\u00ae drug delivery technology: a novel approach to subcutaneous administration using recombinant human hyaluronidase PH20","volume":"26","author":"Locke","year":"2019","journal-title":"Drug Deliv"},{"issue":"4","key":"10.1016\/j.annonc.2023.05.009_bib21","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1055\/s-0034-1368173","article-title":"Subcutaneous administration of monoclonal antibodies in oncology","volume":"74","author":"Jackisch","year":"2014","journal-title":"Geburtshilfe Frauenheilkd"},{"key":"10.1016\/j.annonc.2023.05.009_bib22","unstructured":"US Food and Drug Administration. Hylenex. Highlights of Prescribing Information. 2016. Available at https:\/\/hylenex.com\/downloads\/approved-uspi-lbl301feb2016.pdf (Accessed 28 November 2022)."},{"issue":"5","key":"10.1016\/j.annonc.2023.05.009_bib23","doi-asserted-by":"crossref","first-page":"e370","DOI":"10.1016\/S2352-3026(20)30070-3","article-title":"Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicentre, open-label, non-inferiority, randomised, phase 3 trial","volume":"7","author":"Mateos","year":"2020","journal-title":"Lancet Haematol"},{"issue":"5","key":"10.1016\/j.annonc.2023.05.009_bib24","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1002\/cpt.2308","article-title":"Quantitative clinical pharmacology supports the bridging from i.v. dosing and approval of s.c. rituximab in B-cell hematological malignancies","volume":"110","author":"Jamois","year":"2021","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"10.1016\/j.annonc.2023.05.009_bib25","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/S1470-2045(20)30536-2","article-title":"Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection plus chemotherapy in HER2-positive early breast cancer (FeDeriCa): a randomised, open-label, multicentre, non-inferiority, phase 3 study","volume":"22","author":"Tan","year":"2021","journal-title":"Lancet Oncol"},{"issue":"9","key":"10.1016\/j.annonc.2023.05.009_bib26","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1016\/S1470-2045(12)70329-7","article-title":"Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I-III breast cancer (HannaH study): a phase 3, open-label, multicentre, randomised trial","volume":"13","author":"Ismael","year":"2012","journal-title":"Lancet Oncol"},{"issue":"10","key":"10.1016\/j.annonc.2023.05.009_bib27","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1002\/cpdd.936","article-title":"Results of a dose-finding phase 1b study of subcutaneous atezolizumab in patients with locally advanced or metastatic non\u2013small cell lung cancer","volume":"10","author":"Felip","year":"2021","journal-title":"Clin Pharmacol Drug Dev"},{"key":"10.1016\/j.annonc.2023.05.009_bib28","unstructured":"VENTANA PD-L1 (SP142) Assay [package insert]. Tucson, AZ: Ventana Medical Systems Inc; 2020. Available at https:\/\/www.accessdata.fda.gov\/cdrh_docs\/pdf16\/p160002c.pdf (Accessed 28 November 2022)."},{"key":"10.1016\/j.annonc.2023.05.009_bib29","series-title":"Multiple Comparison Procedures","author":"Hochberg","year":"1987"},{"key":"10.1016\/j.annonc.2023.05.009_bib30","unstructured":"US Department of Health and Human Services. Food and Drug Administration. Center for Drug Evaluation and Research (CDER). Statistical approaches to establishing bioequivalence guidance for industry. 2022. Available at https:\/\/www.fda.gov\/media\/163638\/download (Accessed 20 June 2023)."},{"key":"10.1016\/j.annonc.2023.05.009_bib31","unstructured":"European Medicines Agency. Committee for Medicinal Products for Human Use (CHMP). Guideline on the investigation of bioequivalence. 2010. Available at https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-investigation-bioequivalence-rev1_en.pdf. (Accessed 20 June 2023)."},{"key":"10.1016\/j.annonc.2023.05.009_bib32","doi-asserted-by":"crossref","unstructured":"Hauck W, Anderson S. A comparison of large-sample confidence interval methods for the difference of two binomial probabilities. Am\u00a0Stat. 40(4):318-322.","DOI":"10.1080\/00031305.1986.10475426"},{"issue":"11","key":"10.1016\/j.annonc.2023.05.009_bib33","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1002\/jcph.2074","article-title":"Extension of the alternative intravenous dosing regimens of atezolizumab into combination settings through modeling and simulation","volume":"62","author":"Liu","year":"2022","journal-title":"J\u00a0Clin Pharmacol"},{"issue":"2","key":"10.1016\/j.annonc.2023.05.009_bib34","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1002\/cpt.587","article-title":"Clinical pharmacokinetics and pharmacodynamics of atezolizumab in metastatic urothelial carcinoma","volume":"102","author":"Stroh","year":"2017","journal-title":"Clin Pharmacol Ther"},{"issue":"6","key":"10.1016\/j.annonc.2023.05.009_bib35","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1007\/s00280-019-03954-8","article-title":"Alternative dosing regimens for atezolizumab: an example of model-informed drug development in the postmarketing setting","volume":"84","author":"Morrissey","year":"2019","journal-title":"Cancer Chemother Pharmacol"},{"issue":"5","key":"10.1016\/j.annonc.2023.05.009_bib36","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1002\/cpt.656","article-title":"Association of time-varying clearance of nivolumab with disease dynamics and its implications on exposure response analysis","volume":"101","author":"Liu","year":"2017","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"10.1016\/j.annonc.2023.05.009_bib37","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/s00280-021-04276-4","article-title":"Time-dependent population PK models of single-agent atezolizumab in patients with cancer","volume":"88","author":"Marchand","year":"2021","journal-title":"Cancer Chemother Pharmacol"},{"issue":"7","key":"10.1016\/j.annonc.2023.05.009_bib38","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/S1470-2045(19)30167-6","article-title":"Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial","volume":"20","author":"West","year":"2019","journal-title":"Lancet Oncol"},{"issue":"24","key":"10.1016\/j.annonc.2023.05.009_bib39","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1056\/NEJMoa1716948","article-title":"Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC","volume":"378","author":"Socinski","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"suppl 15","key":"10.1016\/j.annonc.2023.05.009_bib40","doi-asserted-by":"crossref","first-page":"9002","DOI":"10.1200\/JCO.2021.39.15_suppl.9002","article-title":"Pooled analyses of immune-related adverse events (irAEs) and efficacy from the phase 3 trials IMpower130, IMpower132, and IMpower150","volume":"39","author":"Socinski","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"10.1016\/j.annonc.2023.05.009_bib41","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1111\/cts.13127","article-title":"Evaluation of atezolizumab immunogenicity: clinical pharmacology (part 1)","volume":"15","author":"Wu","year":"2022","journal-title":"Clin Transl Sci"},{"issue":"5","key":"10.1016\/j.annonc.2023.05.009_bib42","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1208\/s12248-015-9782-0","article-title":"C\u00a0Clinical immunogenicity of rHuPH20, a hyaluronidase enabling subcutaneous drug administration","volume":"17","author":"Rosengren","year":"2015","journal-title":"AAPS J"},{"key":"10.1016\/j.annonc.2023.05.009_bib43","unstructured":"US Food and Drug Administration. Herceptin HYLECTA. Highlights of Prescribing Information. 2019. Available at https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/761106s000lbl.pdf (Accessed 28 November 2022)."},{"key":"10.1016\/j.annonc.2023.05.009_bib44","unstructured":"US Food and Drug Administration. Rituxan HYCELA. Highlights of Prescribing Information. 2017. Available at https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/761064s000lbl.pdf (Accessed 28 November 2022)."},{"key":"10.1016\/j.annonc.2023.05.009_bib45","unstructured":"US Food and Drug Administration. Phesgo. Highlights of Prescribing Information. 2020. Available at https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/761170s000lbl.pdf (Accessed 20 June 2023)."}],"updated-by":[{"DOI":"10.1016\/j.annonc.2023.12.005","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000}}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753423006944?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753423006944?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,18]],"date-time":"2024-10-18T09:56:47Z","timestamp":1729245407000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753423006944"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":45,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["S0923753423006944"],"URL":"https:\/\/doi.org\/10.1016\/j.annonc.2023.05.009","relation":{"erratum":[{"id-type":"doi","id":"10.1016\/j.annonc.2023.12.005","asserted-by":"object"}]},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"IMscin001 Part 2: a randomised phase III, open-label, multicentre study examining the pharmacokinetics, efficacy, immunogenicity, and safety of atezolizumab subcutaneous versus intravenous administration in previously treated locally advanced or metastatic non-small-cell lung cancer and pharmacokinetics comparison with other approved indications","name":"articletitle","label":"Article Title"},{"value":"Annals of Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.annonc.2023.05.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}]}}